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Triaging multiple myeloma patients for stem cell transplantation
relies heavily on the identiﬁcation of high-risk prognostic factors.
Although a variety of molecular cytogenetic methods are widely
utilized, it is not clear which, if any, has a greater value than others.
In addition, identiﬁcation of the best test(s) would assist in con-
serving valuable resources, especially at smaller centers. We con-
ducted a comparative study on the bone marrow aspirates of 74
consecutive patients with Salmon-Durie Stage I, II, or III disease.
The majority (59/74) of patients were clinically in advanced stage
and planned to undergo therapy. On each patient, image analysis of
morphologically selected interphase plasmacytes was utilized to
ascertain the DNA ploidy level and karyotype analysis was at-
tempted on metaphases obtained following cell culture. Fluores-
cence in situ hybridization (FISH) for RB1 and TP53 was per-
formed in all cases with 	30% bone marrow plasmacytes. Neither
the detection of hypodiploidy or hyperdiploidy by image analysis
or the deletion of TP53 by FISH correlated with survival (P .871
and P  .792, respectively). Deletion of the RB1 locus was ob-
served in 27% of patients tested and tended to signiﬁcance (P 
.270). A karyotype was achieved in 43% of patients. An abnormal
karyotype was observed only in Stage III patients and was signiﬁ-
cantly linked to poor survival by Kaplan-Meier analysis (P  .002).
Evaluating a small cohort with a short observation period and using
the endpoint of death, highlights those tests most linked to ad-
vanced stage disease and identiﬁes those patients most likely to
beneﬁt from stem cell transplantation. A cost-effective algorithm is
suggested in which cytogenetic analysis is performed only on Stage
III patients and FISH for a 13q14 locus alone is performed in those
with 	30% bone marrow plasmacytes.
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Introduction: Recent data demonstrate that large cell transfor-
mation (TR) of follicular lymphoma (TRFL) has a different gene
expression proﬁle than diffuse large cell lymphoma (DL). Out-
comes of salvage chemotherapy and autologous stem cell trans-
plantation (ASCT) for TRFL are unclear. We compared the over-
all response rate (ORR) to salvage chemotherapy, progression-free
(PFS) and overall survival (OS) of TRFL patients (pts) to pts with
relapsed or refractory (RR) DL. Methods: We reviewed cases
between January 1995 and December 2004 and identiﬁed 56 pts
with biopsy proven DL that had arisen from Follicular Grade 1 or
2 lymphoma treated with chemotherapy with the intent to proceed
to ASCT. One hundred forty-three consecutive pts with RR-DL
who received salvage chemotherapy between January 1, 1999 and
December 31, 2004 served as a control. Pts received anthracycline
or platinum-based salvage therapy to assess chemotherapy sensi-
tivity; responders proceeded to PBSC mobilization and ASCT.
The intensive therapy regimen consisted of high-dose etoposide 60
mg/kg day 4 and melphalan 180 mg/m2 day 3 (with or without
1200 cGy TBI in 6 fractions) with PBSC infusion day 0. Results:
The median age at the initiation of salvage chemotherapy was 54
years (range 31–65) in the TRFL pts versus 53 (21–66) in the
RR-DLBCL pts (P  .31, Wilcoxon). The median time from
diagnosis of FL to diagnosis of TRFL was 4 years (range 0.6–23).
Advanced stage disease at TR was found in 78% of TRFL pts
versus 52% of RR-DLBCL pts (P  .0007 -square). The median
number of treatments for TRFL pts was 2 (range 0–8) while the
median number of prior treatments for RR-DLBCL was 1 (range
1–3). The ORR to ﬁrst line salvage chemotherapy was 50% in
TRFL pts versus 48% in RR-DLBCL pts (P  .79 -square). 50%
of TRFL and 45% of RR-DLBCL pts were able to proceed to
ASCT after all salvage chemotherapy and PBSC mobilization (P
.53, -square). For chemosensitive pts who underwent ASCT, the
2 year OS was similar (36% TRFL, 53% RR-DLBCL, P  .15)
while the 2 year PFS was inferior for TRFL (20% TRFL, 36%
RR-DLBCL, P  .04), with a similar median follow-up in both
groups (TRFL: 2 years, RR-DL 1.8 years). Conclusions: Pts with
TRFL were more likely to have advanced stage disease and were
more pre-treated prior to salvage therapy. The ORR to salvage
chemotherapy was similar but TRFL pts had an inferior PFS
(though not OS) post-ASCT. Studies should focus on developing
prognostic models to risk stratify TRFL, and novel therapies
should be considered.
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Several prognostic factors had been previously reported to be
associated with overall and progression-free survival of patients
with NHL after APSCT. We present a retrospective single center
analysis with special attention to the markers that reﬂect the ac-
tivity of disease at the time of transplantation. 122 patients with
NHL indicated for APSCT for high-risk features at diagnosis
partial response to ﬁrst line treatment and/or relapse were included
in the study. There were 66 women and 56 men at median age 45.5
years (range 19–66). Forty-seven patients were with diagnosis of
diffuse-large cell lymphoma, 34 with follicular lymphoma, 15 with
mantle cell lymphoma, and 26 patients had other lymphoma sub-
types. Patients were transplanted in years 1997–2004. In all cases,
BEAM was used for conditioning. Median follow-up of patients
was 27 months (range 3.0–93.9). Fifty (41%) patients relapsed and
35 (28.7%) died. Age, stage of disease, IPI, bone marrow and
extra-nodal involvement, presence of B symptoms and bulky dis-
ease at diagnosis, activity of disease and Karnofski index at the time
of transplantation, response to therapy and levels of serologic
markers (LDH, -2-microglobulin and thymidine kinase) at the
diagnosis and at the time of transplantation were included in
univariate and multivariate analysis. For relapse-free survival level
of LDH at transplantation was identiﬁed as signiﬁcant factor both
in univariate analysis and Cox regression model (RR  3.63; 95%
CI 1.02–12.88, P .046). On the other hand, levels of LDH and
thymidine kinase at diagnosis and levels of LDH, thymidine kinase
and -2-microglobulin together with Karnofski score at transplan-
tation and age were found predictive for overall survival in univar-
iate analysis. Multivariate Cox regression analysis identiﬁed levels
of -2-microglobulin at transplantation (RR  2.59; 95% CI 
1.06–6.37, P  .038) and LDH at transplantation (RR  1.08;
95% CI  1.02–1.15, P  .007) as independent prognostic factors.
We conclude that clinical assessment of disease activity at trans-
plantation was not sufﬁcient for estimation of prognosis in our
patients. Levels of serologic markers as LDH and -2-microglobu-
lin at transplantation were found more useful and signiﬁcantly
correlated with overall survival of our patients with NHL after
APSCT. Supported by grant MSM 6198959205.
345
TOTAL MARROW IRRADIATION AND PERIPHERAL BLOOD PROGENI-
TOR CELL RESCUE FOLLOWING HIGH-DOSE MELPHALAN AND PERIPH-
ERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH MULTI-
PLE MYELOMA
Somlo, G.1, Forman, S.1, Popplewell, L.1, Spielberger, R.2, Sahebi, F.2,
Parker, P.1, Schultheiss, T.1, Liu, A.1, Krishnan, A.1, Wong, J.1 1. City
of Hope National Medical Center, Duarte, CA; 2. Kaiser Permanente,
Los Angeles, CA.
Tandem high-dose therapy (THDT) followed by peripheral
blood progenitor cell reinfusion (PBPC) is associated with a pro-
jected 20% progression-free survival at 7 years after treatment for
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